On the Couch with Paul Rennie – CEO Paradigm Pharma (PAR)

Welcome to the another episode of 'On the Couch'. This occasional podcast series of chats with fund managers, CEO’s and brokers aims to give you an insight into the investing world. In this episode, Henry Jennings is joined by Paul Rennie, the Founder and Executive Chairman at Paradigm (PAR). Paul is recognised as a leading authority in drug development and has been involved in a number of pre-clinical and clinical trial programs over his accomplished career. He was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd. Paul has broad experience in commercialising Intellectual Property.
  • Paradigm Biopharmaceuticals is a late-stage drug development company working with some of the world’s leaders in pharmaceutical product development and approaching science from a completely different angle.
  • The immediate commercial focus is the development of injectable pentosan polysulfate sodium (iPPS/PPS, brand name Zilosul®) for the treatment of osteoarthritis (OA). This is a global unmet need and Paradigm has advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain and regeneration, PPS has genuine disease modifying potential.
  • Pentosan polysulfate sodium (PPS) is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs).
  Disclaimer: This is general advice only and you should consult your financial adviser regarding any of the thoughts, ideas or insights in this podcast.   More about the author – Henry Jennings Henry Jennings, Senior Market Analyst and Media Commentator at Marcus Today Stock Market Newsletter, has been involved in financial markets since the 80s in London before emigrating to Australia. He first joined Deutsche Bank and then Macquarie Bank as Head of Equity Trading in Sydney. Since leaving Macquarie, Henry has been both an institutional and private client adviser. For the last seven years, Henry has been writing strategy and insights daily and is a frequent media commentator on all things finance on ABC TV and Radio, SBS and Ausbiz. He also hosts a series of podcasts talking to industry experts and the popular live Ask the Analyst session for Marcus Today.

Get access to more market commentary, sign up for a free trial now and become a better investor.

Members Only - Login to read full article

Remember Me

Error logging you in.
Please check your details and try again.